TNFRSF10B and myocardial infarction: Excessive cardiac cell death, a primary pathological feature of myocardial infarction (MI), can be substantially alleviated by inhibiting TRAIL with DR5 antagonists, such as sDR5-Fc fusion proteins, which have been shown to improve outcomes following myocardial infarction (MI).